CLINICAL_TRIALS
trial_result
· 2022-05-05
Clinical Trial Update: Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO) [Phase 2]
Summary
Phase 2 trial update on AEMCOLO (Rifamycin SV MMX) for small intestinal bacterial overgrowth (SIBO) with unclear status.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bradley Connor | Conditions: Small Intestinal Bacterial Overgrowth, Gastrointestinal Disease | Phase 2 | Status: UNKNOWN